Brooke Gessner, Michelle Carter, Kiana Rahnama, Alberto Almeida, Colleen Borralho, Tamara Mihic, Joan C Y Ng, Joseph H Puyat, Angela Russolillo, Katelyn C Halpape
INTRODUCTION: Clozapine is the most effective antipsychotic in the management of treatment-resistant schizophrenia; however, its use is challenging due to the risk of severe adverse effects. Despite the risks associated with clozapine, there is no mandatory monitoring in Canada beyond hematologic testing for agranulocytosis surveillance. This study focuses on the development, implementation, and evaluation of a clozapine clinical toolkit (CTK) targeted at optimizing inpatient clozapine use...
April 2024: Mental Health Clinician